{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:27:07Z","timestamp":1791311227917,"version":"4.3.1"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T00:00:00Z","timestamp":1452211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,1,8]],"date-time":"2016-01-08T00:00:00Z","timestamp":1452211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2015.109","type":"journal-article","created":{"date-parts":[[2016,1,9]],"date-time":"2016-01-09T04:16:43Z","timestamp":1452313003000},"page":"e377-e377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["PPAR\u03b3 ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells"],"prefix":"10.1038","volume":"6","author":[{"given":"E","family":"Glodkowska-Mrowka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Manda-Handzlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Stelmaszczyk-Emmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Seferynska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Stoklosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Przybylski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4300-7267","authenticated-orcid":false,"given":"P","family":"Mrowka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,8]]},"reference":[{"key":"BFbcj2015109_CR1","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1172\/JCI35721","volume":"121","author":"AS Corbin","year":"2011","unstructured":"Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ . Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011; 121: 396\u2013409.","journal-title":"J Clin Invest"},{"key":"BFbcj2015109_CR2","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/leu.2014.245","volume":"29","author":"AM Eiring","year":"2015","unstructured":"Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia 2015; 29: 586\u2013597.","journal-title":"Leukemia"},{"key":"BFbcj2015109_CR3","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.1172\/JCI68951","volume":"123","author":"P Neviani","year":"2013","unstructured":"Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013; 123: 4144\u20134157.","journal-title":"J Clin Invest"},{"key":"BFbcj2015109_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nature15248","volume":"525","author":"S Prost","year":"2015","unstructured":"Prost S, Relouzat F, Spentchian M, Ouzegdouh Y, Saliba J, Massonnet G et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists. Nature 2015; 525: 380\u2013383.","journal-title":"Nature"},{"key":"BFbcj2015109_CR5","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","volume":"124","author":"S Branford","year":"2014","unstructured":"Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood 2014; 124: 511\u2013518.","journal-title":"Blood"},{"key":"BFbcj2015109_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.exphem.2014.02.006","volume":"42","author":"E Glodkowska-Mrowka","year":"2014","unstructured":"Glodkowska-Mrowka E, Mrowka P, Basak GW, Niesiobedzka-Krezel J, Seferynska I, Wlodarski PK et al. Statins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinib. Exp Hematol 2014; 42: 439\u2013447.","journal-title":"Exp Hematol"},{"key":"BFbcj2015109_CR7","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1182\/blood.V124.21.1804.1804","volume":"124","author":"D Kim","year":"2014","unstructured":"Kim D, Alfraih F, Lee H, Lipton J. The Use of Statin Enhances Chance of Achieving MR4.5 in Chronic Myeloid Leukemia Patients in Chronic Phase Following Imatinib Therapy. Blood 2014; 124: 1804.","journal-title":"Blood"},{"key":"BFbcj2015109_CR8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ahj.2014.07.016","volume":"168","author":"CM Viscoli","year":"2014","unstructured":"Viscoli CM, Brass LM, Carolei A, Conwit R, Ford GA, Furie KL et al. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. Am Heart J 2014; 168: 823\u20139 e6.","journal-title":"Am Heart J"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj2015109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj2015109","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj2015109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T09:04:28Z","timestamp":1672823068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj2015109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,8]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1]]}},"alternative-id":["BFbcj2015109"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2015.109","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,8]]},"assertion":[{"value":"8 January 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}